New activity is brewing for Sonnet BioTherapeutics Holdings ( ($SONN) ). The company has submitted a Form DEFM14A to the SEC, indicating an ...
Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 ...
Sonnet BioTherapeutics Holdings, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent related to its modified form of Interleukin-18, ...
Company advancing development of its modified version of Interleukin-18 (IL-18Binding Protein Resistant or IL-18BPR) that exhibits wild-type binding to the IL-18 receptor (IL-18Rc), coupled with ...